See more : Forus S.A. (FORUS.SN) Income Statement Analysis – Financial Results
Complete financial analysis of Finch Therapeutics Group, Inc. (FNCH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Finch Therapeutics Group, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Safehold Inc. (SAFE) Income Statement Analysis – Financial Results
- TAAT Global Alternatives Inc. (TAAT.CN) Income Statement Analysis – Financial Results
- Seabridge Gold Inc. (SEA.TO) Income Statement Analysis – Financial Results
- Lions Gate Entertainment Corp. (LGF-A) Income Statement Analysis – Financial Results
- UC&GN International Corp. (3603.TWO) Income Statement Analysis – Financial Results
Finch Therapeutics Group, Inc. (FNCH)
About Finch Therapeutics Group, Inc.
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 107.00K | 861.00K | 18.53M | 7.72M | 10.15M |
| Cost of Revenue | 7.20M | 5.51M | 57.28M | 33.14M | 314.00K |
| Gross Profit | -7.09M | -4.65M | -38.75M | -25.43M | 9.84M |
| Gross Profit Ratio | -6,628.04% | -539.61% | -209.08% | -329.38% | 96.91% |
| Research & Development | 7.20M | 57.89M | 57.28M | 33.14M | 23.54M |
| General & Administrative | 26.91M | 38.09M | 21.24M | 14.01M | 7.44M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 26.91M | 38.09M | 21.24M | 14.01M | 7.44M |
| Other Expenses | 0.00 | 947.00K | 1.83M | 2.00K | 40.00K |
| Operating Expenses | 32.59M | 95.98M | 78.52M | 47.16M | 30.98M |
| Cost & Expenses | 34.11M | 95.98M | 78.52M | 47.16M | 31.30M |
| Interest Income | 1.57M | 252.00K | 22.00K | 106.00K | 488.00K |
| Interest Expense | 0.00 | 35.44M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.52M | 5.51M | 2.30M | 790.00K | 482.00K |
| EBITDA | -32.48M | -82.69M | -57.68M | -38.65M | -20.66M |
| EBITDA Ratio | -30,357.01% | -8,669.80% | -323.68% | -500.49% | -202.09% |
| Operating Income | -34.00M | -115.59M | -59.99M | -39.44M | -21.14M |
| Operating Income Ratio | -31,777.57% | -13,425.44% | -323.68% | -510.90% | -208.21% |
| Total Other Income/Expenses | -44.21M | 947.00K | 1.83M | 95.00K | 388.00K |
| Income Before Tax | -78.22M | -114.65M | -58.16M | -39.34M | -20.75M |
| Income Before Tax Ratio | -73,098.13% | -13,315.45% | -313.84% | -509.66% | -204.39% |
| Income Tax Expense | -3.46M | -947.00K | -2.30M | -93.00K | -348.00K |
| Net Income | -74.75M | -113.70M | -55.86M | -39.25M | -20.41M |
| Net Income Ratio | -69,863.55% | -13,205.46% | -301.42% | -508.46% | -200.97% |
| EPS | -46.59 | -71.52 | -35.27 | -24.39 | -12.68 |
| EPS Diluted | -46.59 | -71.52 | -35.27 | -24.39 | -12.68 |
| Weighted Avg Shares Out | 1.60M | 1.59M | 1.58M | 1.61M | 1.61M |
| Weighted Avg Shares Out (Dil) | 1.60M | 1.59M | 1.58M | 1.61M | 1.61M |
Finch Announces Delisting from Nasdaq and SEC Deregistration
4 Penny Stocks To Buy According To Analysts, Targets Up To 1,650%
Finch Therapeutics Group, Inc. (FNCH) Reports Q3 Loss, Misses Revenue Estimates
Finch Therapeutics Group, Inc. (FNCH) Upgraded to Buy: Here's Why
Finch Therapeutics to Host Corporate Update Conference Call and Webcast on May 16, 2022
Why Finch Therapeutics Stock Is Skyrocketing Today
Why Is Finch Therapeutics (FNCH) Stock Up 30% Today?
Best Penny Stocks to Buy Today? 3 to Watch on April 29th
Finch Therapeutics' C. Difficile Infection Candidate Meets Primary Goal In Mid-Stage Study
Finch Therapeutics to Present at the Jefferies Virtual Next Generation IBD Therapeutics Summit
Source: https://incomestatements.info
Category: Stock Reports